According to GSK, the facility represents a £44m investment which, when fully operational in 2019, will provide ingredients for more than 40 million vaccinations a year.
The company told in-PharmaTechnologist the plant will create 15 jobs, on a site which employs more than 450.
The salts plant is situated within GSK’s Montrose facility, which has been making drug ingredients – including APIs for respiratory and HIV vaccine products – for six decades.
Last month, GSK announced it would restructure its UK network by suspending plans for its Ulverston, Italy-based biopharma plant.
In addition, the firm suggested it would sell its cephalosporin antibiotics business and associated facilities, and invest in HIV and respiratory drug capacity.
The company said it is simplifying its business by improving competitiveness of its manufacturing network and increasing focus on its core business.